Hospital
ST Elizabeth Medical Center, INC
ST Elizabeth Medical Center, INC was paid $35.42M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoST ELIZABETH MEDICAL CENTER, INC
WILLIAMSTOWN, KY 41097
WILLIAMSTOWN, KY 41097
33aNPI1114974813assigned 05/28/2006
33bProvider typeCritical Access Hospital
28Total paid$35.42M
24GClaims394,581
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#1 of 16
Median peer was paid$11.73M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,516 | $4.41M | |
| 2019 | 51,146 | $4.57M | |
| 2020 | 46,889 | $4.42M | |
| 2021 | 56,001 | $4.96M | |
| 2022 | 62,582 | $5.45M | |
| 2023 | 67,681 | $6.31M | |
| 2024incomplete | 54,766 | $5.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 27,755 | 24,883 | $9.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 10,326 | 9,084 | $5.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 5,578 | 4,287 | $3.65M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 12,233 | 7,313 | $1.62M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 7,407 | 7,003 | $1.46M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 4,258 | 3,928 | $1.38M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 6,984 | 3,041 | $925K |
| 36415 | Collection of venous blood by venipuncture | 2.1% | 49,467 | 28,069 | $757K |
| J3490 | Unclassified drugs | 1.6% | 19,439 | 8,960 | $550K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 8,218 | 4,986 | $548K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 9,507 | 3,241 | $520K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 11,315 | 5,491 | $500K |
180 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.3% | 783 | $477K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 8,310 | $450K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 5,968 | $412K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 5,852 | $369K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 1,671 | $358K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,354 | $328K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,173 | $304K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,999 | $296K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,871 | $227K |
| 72100 | <1% | 2,005 | $208K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,742 | $185K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 438 | $182K |
| 73630 | <1% | 2,258 | $173K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,463 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,241 | $161K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,630 | $146K |
| 73564 | <1% | 1,298 | $138K | |
| 73610 | <1% | 1,857 | $137K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 748 | $133K |
| 73130 | <1% | 1,641 | $131K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,931 | $112K |
| 73030 | <1% | 1,430 | $109K | |
| 96376 | <1% | 1,467 | $102K | |
| 76830 | Ultrasound, transvaginal | <1% | 740 | $96K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 498 | $95K |
| 84484 | <1% | 6,917 | $92K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 507 | $90K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,001 | $86K |
| 97161 | <1% | 942 | $83K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 436 | $80K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,472 | $76K |
| 84702 | <1% | 4,680 | $76K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,705 | $75K |
| 73110 | <1% | 972 | $73K | |
| 71271 | <1% | 689 | $60K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 735 | $51K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 732 | $48K |
| 85027 | <1% | 6,729 | $46K | |
| 83690 | <1% | 5,403 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,470 | $43K |
| 74018 | <1% | 559 | $43K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,165 | $41K |
| 80061 | Lipid panel | <1% | 2,732 | $41K |
| 82565 | <1% | 1,634 | $39K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 678 | $39K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,456 | $36K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 93 | $34K |
| 12001 | <1% | 302 | $34K | |
| 83880 | <1% | 856 | $34K | |
| 83605 | <1% | 2,759 | $34K | |
| 29125 | <1% | 199 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,128 | $31K |
| 71250 | <1% | 360 | $29K | |
| 81001 | <1% | 6,456 | $27K | |
| 82077 | <1% | 862 | $27K | |
| 87631 | <1% | 182 | $27K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 480 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,870 | $26K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 218 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,984 | $24K |
| 87430 | <1% | 1,235 | $23K | |
| 82803 | <1% | 778 | $23K | |
| 73502 | <1% | 275 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 269 | $21K |
| 82962 | <1% | 2,605 | $19K | |
| 80076 | <1% | 1,905 | $18K | |
| 72050 | <1% | 180 | $18K | |
| 85379 | <1% | 1,506 | $18K | |
| 80306 | <1% | 995 | $18K | |
| 85610 | <1% | 3,350 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,731 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 378 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 377 | $16K |
| 84703 | <1% | 1,356 | $16K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 75 | $15K |
| 73140 | <1% | 210 | $14K | |
| 87040 | <1% | 1,105 | $14K | |
| 84439 | <1% | 1,191 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,564 | $14K |
| 73080 | <1% | 209 | $13K | |
| 82607 | <1% | 610 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,247 | $13K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 302 | $12K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 663 | $12K |
| 83735 | <1% | 1,473 | $12K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 33 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 332 | $11K |
| 90715 | <1% | 348 | $11K | |
| 81003 | <1% | 3,011 | $10K | |
| 73562 | <1% | 120 | $10K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,245 | $9K |
| 87077 | <1% | 692 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 77 | $8K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 137 | $8K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 600 | $8K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 610 | $7K |
| 86140 | <1% | 1,108 | $6K | |
| 76770 | <1% | 59 | $6K | |
| 10060 | <1% | 56 | $6K | |
| 87186 | <1% | 542 | $5K | |
| 76536 | <1% | 39 | $5K | |
| 82746 | <1% | 271 | $5K | |
| 84145 | <1% | 189 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $5K |
| 97162 | <1% | 42 | $5K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 152 | $5K |
| 96367 | <1% | 61 | $5K | |
| 12002 | <1% | 45 | $4K | |
| 93971 | <1% | 44 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,496 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 175 | $4K |
| 93225 | <1% | 31 | $4K | |
| 85652 | <1% | 1,171 | $4K | |
| 70498 | <1% | 27 | $4K | |
| 82728 | <1% | 181 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 120 | $3K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 35 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,030 | $3K |
| 83540 | <1% | 359 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 66 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,117 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 25 | $2K |
| 83550 | <1% | 210 | $2K | |
| 80305 | <1% | 137 | $2K | |
| 82570 | <1% | 278 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 126 | $2K |
| 36591 | <1% | 16 | $2K | |
| 12011 | <1% | 12 | $2K | |
| 70491 | <1% | 12 | $2K | |
| 85730 | <1% | 255 | $2K | |
| 73090 | <1% | 16 | $2K | |
| 87807 | <1% | 103 | $2K | |
| 72070 | <1% | 15 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 133 | $1K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 517 | $1K |
| 82805 | <1% | 39 | $1K | |
| 73590 | <1% | 28 | $1K | |
| 80074 | <1% | 24 | $1K | |
| 93226 | <1% | 14 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 561 | $1K |
| 80069 | <1% | 98 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $934.64 |
| 87808 | <1% | 54 | $914.49 | |
| 80143 | <1% | 12 | $886.88 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 104 | $678.14 |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $676.37 |
| 86901 | <1% | 79 | $655.49 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $651.13 |
| 86900 | <1% | 63 | $629.28 | |
| 86780 | <1% | 37 | $484.61 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 14 | $405.80 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 275 | $403.54 |
| 84550 | <1% | 72 | $323.57 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 14 | $316.89 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 172 | $294.88 |
| 87088 | <1% | 29 | $265.80 | |
| 86803 | <1% | 12 | $254.51 | |
| 83516 | <1% | 12 | $241.03 | |
| 97010 | <1% | 30 | $205.79 | |
| 86038 | <1% | 12 | $189.64 | |
| 87340 | <1% | 12 | $181.94 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 33 | $158.26 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 63 | $134.92 |
| 84156 | <1% | 29 | $132.90 | |
| 82248 | <1% | 23 | $131.91 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 17 | $131.72 |
| 82043 | <1% | 12 | $127.95 | |
| 82247 | <1% | 19 | $111.59 | |
| 82550 | <1% | 12 | $110.33 | |
| 87205 | <1% | 28 | $102.37 | |
| 86430 | <1% | 14 | $90.97 | |
| 84100 | <1% | 22 | $78.25 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 35 | $27.29 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 30 | $22.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14 | $15.66 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 26 | $13.76 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 37 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 33 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRITCHEY-BALDWIN, LORI (CFO (INTERIM))
| Provider | Location | Paid |
|---|---|---|
| ST Elizabeth Medical Center, INC | Edgewood, KY | $188.25M |
| ST Elizabeth Medical Center, INC | Florence, KY | $65.44M |
| ST Elizabeth Medical Center, INC | Fort Thomas, KY | $45.99M |
| ST Elizabeth Medical Center, INC | Lawrenceburg, IN | $4.66M |
| ST Elizabeth Medical Center, INC | Erlanger, KY | $3.75M |
| ST Elizabeth Medical Center, INC | Edgewood, KY | $2.95M |
| ST. Elizabeth Medical Center, INC. | Edgewood, KY | $438.18 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.